Power Analytics Global's De-SPAC: What Investors Need to Know
Power Analytics Global is a private AI, advanced analytics, and quantum-resistant security company going public through a merger with Drugs Made In America Acquisition Corp. (DMAA). The setup has upside if signed contracts convert into real revenue, but shareholders should watch valuation resets, redemption risk, and dilution.
Power Analytics Global is a private AI, advanced analytics, and quantum-resistant security company going public through a merger with Drugs Made In America Acquisition Corp. (DMAA). The setup has upside if signed contracts convert into real revenue, but shareholders should watch valuation resets, redemption risk, and dilution.
Deal at a Glance
SPAC partner: Drugs Made In America Acquisition Corp.
SPAC ticker (trades now): DMAA
Implied valuation: $1.0B EV
Expected close: late Q3 2026
Est. first trading date: late Q3 2026
Deal status: Announced
Source filing: SEC 425 (2026-07-20)
Company Overview
Power Analytics Global Corp. (PAGC) is described in the merger agreement as a private company focused on artificial intelligence, advanced analytics, and quantum-resistant security solutions. The deal documents say PAGC is contributing the operating business and management expertise to the combined company, and that post-close leadership will come from PAGC’s designees.
The public record surfaced here does not include a full company profile, product list, customer roster, headquarters, founding year, employee count, ARR, backlog, or audited financial statements. What is disclosed is more specific than a typical SPAC pitch in one respect: PAGC must show commercial traction through executed or substantially negotiated revenue contracts, and the valuation framework is tied to the verified value of those contracts. That puts this deal in the enterprise software / cybersecurity / AI infrastructure lane, but the filings do not provide a formal TAM, market share, or named competitor set.
The SPAC Deal
Power Analytics Global is merging with Drugs Made In America Acquisition Corp. (NASDAQ: DMAA) in a de-SPAC that was announced and then documented in a definitive merger agreement signed on April 29, 2026, with amendments on April 30, 2026 and July 14, 2026. The agreement targets a $1.0 billion enterprise value at closing, but it also sets a floor valuation of $300 million and ties the final valuation to milestone-based verified contract value: $15 million to $25 million supports a $300 million EV, $25 million to $50 million supports up to $500 million, $50 million to $75 million supports up to $750 million, and $75 million-plus / full execution supports the $1.0 billion target.
This is a classic SPAC mechanics story, not just an operating-company story. DMAA’s trust cash will fund the deal subject to redemptions, taxes, and expenses, but the merger agreement does not disclose the trust balance. The company is targeting minimum cash of $30 million at closing, with flexibility to close at lower levels, but not below $15 million. No firm PIPE commitment was disclosed; the agreement says DMAA may arrange a PIPE in its sole discretion and will use commercially reasonable efforts to raise additional capital if needed. That means redemption risk is real: if too many public shares are redeemed, the cash available to PAGC can shrink quickly.
Dilution is another key issue. DMAA’s 10-K says the sponsor received 22,361,111 founder shares for $35,000, and it also had private placement units plus up to $1.5 million of working-capital loans convertible into units at $10.00 per unit. A July 14, 2026 amendment requires the sponsor to surrender and forfeit at least 50% of its ordinary shares for no consideration, with the rest subject to earnout vesting at $12.50 and $15.00 trading-price hurdles. It also requires surrender of 45,092 ordinary shares tied to an unfunded private placement subscription and 430,000 private placement rights. That helps, but founder-share promote, rights, warrants, and any PIPE still matter. The expected post-merger ticker was not disclosed; the agreement says the combined company will trade on NASDAQ or NYSE and the board of NEWCO will تعیین the ticker. Based on the filing trail, the first trading window is best thought of as late Q3 2026, assuming the SEC process, shareholder vote, and closing steps finish on schedule.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The filings point to a straightforward reason for the SPAC route: capital plus speed. PAGC is using the merger to access public equity while presenting a valuation case anchored to signed or substantially negotiated revenue contracts, rather than relying on a traditional IPO story built around historical financials alone. The structure also gives the company a public listing path while allowing the parties to negotiate valuation milestones and closing conditions directly in the merger agreement.
For investors, the attraction is that the deal is framed around commercial traction and contract value, not just narrative. The tradeoff is that the public record here does not show audited target-company financials, so shareholders are being asked to underwrite a business model and contract pipeline with limited disclosed operating history. That is exactly why de-SPACs can re-rate sharply in either direction once the market sees the actual close terms and post-merger disclosures.
Financial Highlights
The sources reviewed here do not disclose PAGC revenue, growth, margins, losses, cash, or runway. They also do not include audited financial statements or a public-company style income statement. Instead, the merger agreement uses verified contract value as the main economic yardstick, which is unusual and important: the company’s implied value depends on how much signed or enforceable revenue it can show.
The only numeric operating thresholds disclosed are the contract-value milestones and the minimum cash condition at closing. The agreement requires evidence of commercial traction, including executed or substantially negotiated revenue contracts, a debt-free status or payoff schedule, an IP schedule covering software source code, proprietary algorithms, AI/ML models, and quantum-resistant security IP, plus a valid GSA CAGE code. No forward revenue or EBITDA projections were surfaced in the reviewed filings, so any projections would need to come from later SEC materials if they are filed.
Risk Factors
The biggest de-SPAC-specific risk is redemption pressure. DMAA’s trust cash is the main source of closing liquidity, but the actual amount PAGC receives depends on how many public shares are redeemed. The deal targets $30 million of minimum cash, with a floor of $15 million, and there is no disclosed PIPE commitment to backstop a weak redemption outcome. If redemptions are heavy, the combined company could start public life with less cash than investors expect.
Dilution and deal-break risk are the other major issues. DMAA’s sponsor promote is large, even after the required forfeitures and earnout structure, and any PIPE or rights/warrant overhang can further dilute public holders. The merger agreement also gives DMAA room to renegotiate or terminate if PAGC’s valuation falls below $300 million. On top of that, closing still depends on SEC effectiveness, exchange listing approval, and PAGC satisfying the contract, IP, debt, and CAGE-code conditions. In other words, this is not just a vote risk; it is a full execution-risk stack.
Comparable Public Companies
The filings do not provide a formal comp set, so the closest public peers are the names investors would naturally use to frame the business: Palantir (PLTR), CrowdStrike (CRWD), Palo Alto Networks (PANW), BigBear.ai (BBAI), and C3.ai (AI). Those companies sit in AI, analytics, and cybersecurity-adjacent software, which is the same broad lane PAGC is trying to occupy.
I am not inventing valuation multiples from the source set, but the market context is clear: these are established public software names with real operating histories, while PAGC is still a private company with limited disclosed financials. That usually means the market will demand proof of contract conversion and cash generation before it awards a premium multiple. For cross-checking and follow-up, the comp tickers are PLTR, CRWD, PANW, BBAI, and AI.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The setup favors a watchlist approach until the close mechanics are clearer. The deal has a large headline valuation target, but the real story is whether PAGC can prove enough signed contract value to justify that number while avoiding a redemption-driven cash squeeze. Shareholders should watch the final cash-in-trust after redemptions, whether a PIPE appears, and whether the company keeps the valuation near the $1.0 billion target or gets pulled back toward the $300 million floor.
Why this matters now: this is a de-SPAC where the valuation framework is unusually explicit, the sponsor has already given up part of its promote, and the market still does not have a disclosed post-merger ticker or a public operating track record to lean on. That combination can create a sharp re-pricing once the vote and closing details land. The key question is not whether the company has a compelling theme; it is whether the financing, dilution, and contract evidence line up well enough to support the public-market debut.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
